Patient Centered Approaches to Preventing ASCVD Events
Patient Centered Approaches to Preventing ASCVD Events
批准号:
10088461
负责人:
SAMIA MORA
金额:
$12.05万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-01 至 2022-12-31
关键词:
AchievementAddressAgeAmerican Heart AssociationApolipoproteins BAtherosclerosisAutomobile DrivingAwardBiological MarkersBlood VesselsCardiovascular DiseasesCardiovascular systemCenter for Translational Science ActivitiesClinicalCollaborationsCouplingDataDiagnosticDimensionsDiseaseDyslipidemiasEducationEnvironmentEpidemiologyEventGoalsHospitalsIDL lipoproteinsIndividualInstitutionInsulin ResistanceInternationalInvestigationLDL Cholesterol LipoproteinsLeadLipidsLipoproteinsLow-Density LipoproteinsMeasuresMentorsMethodsModernizationMolecularMyocardial InfarctionOutcomeParticipantPathway interactionsPatientsPharmaceutical PreparationsPhenotypePopulationPostdoctoral FellowPreventionPrevention ResearchPreventive MedicinePreventive therapyResearchResearch ActivityResearch PersonnelResearch Project GrantsResidual stateResourcesRiskRisk AssessmentRisk FactorsRisk ManagementRoleScienceSumTeaching HospitalsTestingTrainingUnited Arab EmiratesVery low density lipoproteinWomanWomen&aposs HealthWorkatherosclerosis riskcardiovascular disorder preventioncardiovascular disorder riskcardiovascular healthcardiovascular risk factorcareercareer developmentcase controlcostcost effectiveearly onsetexperiencehigh riskhigh risk populationimprovedinhibitor/antagonistinstrumentationinterestlipoprotein triglyceridemedical schoolsmenmodifiable riskmortalitymultidisciplinarynovelnovel markernovel therapeutic interventionparticlepatient orientedpatient oriented researchpatient populationpersonalized medicinepre-doctoralprematurepreventprogramsprospectiverecruitresearch clinical testingrisk predictiontherapeutic targettraining opportunityyoung adultyoung woman
中文摘要
7.项目摘要/摘要作为一名在流行病学方面接受交叉培训的心脏病专家,莫拉博士致力于
致力于以患者为中心的心血管预防研究,重点关注可改变的风险因素,特别是
脂类。她对预防领域的独立贡献源于一系列深入的研究
研究替代血脂检测在心血管风险预测和管理中的临床应用。她
曾担任20多名患者-博士后和博士后学员的主要研究导师-
以研究项目为导向。近年来,她的指导者在
在国内和国际上展示他们的工作,并得到美国心脏协会杨的认可
研究人员奖和最佳科学摘要会议。在国家层面上,莫拉博士也一直很活跃
在促进女性博士后心血管事业方面。应聘者经验丰富的指导
委员会,正在进行的以患者为中心的研究,卓越的机构资源,以及成本效益
协作为初级调查员的培训和职业发展提供了一个培育环境
以患者为中心的心血管疾病研究。该奖项中提出的新研究目标将评估
两组患者中动脉粥样硬化性心血管疾病(ASCVD)的脂质相关风险:
接受他汀类药物治疗的患者和患有早发性心肌梗死的患者。这一点很重要
临床意义:针对血脂的新治疗策略正在迅速出现,并已进入临床
使用。目前,他汀类药物治疗是血脂异常治疗和心血管预防的基石。
和治疗。然而,在接受他汀类药物治疗的个体中,大多数事件(70%)仍然没有预防
和普通(每7名接受他汀类药物治疗的人中就有1人)。到目前为止,这种“残留风险”背后的机制是
不清楚。虽然人们普遍认为在他汀类药物中导致ASCVD事件的危险因素-
接受治疗的患者与他汀类药物天真的患者相同,新数据表明可能存在
不同之处。此外,尽管过去十年美国的ASCVD总死亡率有所下降,但
最近,年轻人的死亡率没有下降,甚至上升,特别是女性。这个
这项研究的影响是通过确定与血脂相关的血管风险决定因素和
将莫拉博士以患者为导向的研究计划发展和加强为正式的个性化计划
指导重点放在血脂风险因素上。总而言之,这项K24的拟议辅导和研究活动
该项目将为对患者感兴趣的初级调查人员提供大量极好的培训机会-
以心血管研究为导向。
英文摘要
7. Project Summary/Abstract As a cardiologist cross-trained in epidemiology, Dr. Mora has devoted her
career to patient-oriented cardiovascular prevention research, focusing on modifiable risk factors, particularly
lipids. Her independent contributions to the field of prevention resulted from a succession of in-depth studies
examining the clinical utility of alternative lipid testing for cardiovascular risk prediction and management. She
has served as a primary research mentor for more than twenty pre- and post-doctoral trainees in patient-
oriented research projects. This has been highlighted in recent years by the achievements of her mentees in
presenting their work nationally and internationally, with recognition by the American Heart Association Young
Investigator Award and Best of Science abstract sessions. At the national level, Dr. Mora has also been active
in promoting cardiovascular careers for women postdoctoral fellows. The candidate's experienced Mentoring
Committee, ongoing patient-oriented research, exceptional institutional resources, and cost-effective
collaborations provide a nurturing environment for the training and career development of junior investigators in
patient-oriented cardiovascular disease research. The new research aims proposed in this award will evaluate
lipid-related risk of atherosclerotic cardiovascular disease (ASCVD) among two populations of patients: those
who are treated with statins and those who suffer from premature myocardial infarction. This has important
clinical implications as new therapeutic strategies targeting lipids are rapidly emerging and already in clinical
use. Currently, statin therapy is the cornerstone of dyslipidemia management and cardiovascular prevention
and treatment. However, the majority of events (70%) among statin-treated individuals remain unprevented
and common (1 in 7 statin-treated individuals). To this date, the mechanisms underlying this “residual risk” are
unclear. While it is commonly believed that the risk factors responsible for ASCVD events among statin-
treated individuals are the same as those among statin-naïve individuals, new data suggest there may be
differences. Furthermore, while overall ASCVD mortality has declined in the US in the past decade, there has
been no decrease or even an increase in mortality in younger adults recently, in particular for women. The
impact of the study is to improve clinical outcomes by identifying lipid-related determinants of vascular risk and
to grow and strengthen Dr. Mora's patient-oriented research program into a formal individualized program of
mentoring with a focus on lipid risk factors. In sum, the proposed mentoring and research activities of this K24
project will provide numerous excellent training opportunities for junior investigators interested in patient-
oriented cardiovascular research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention
-
批准号:10341419
-
项目类别:
-
资助金额:$78.11万
-
财政年份:2021
-
负责人:SAMIA MORA
-
依托单位:
Targeting the Active Resolution of Inflammation for Cardiovascular Disease Prevention
-
批准号:10531905
-
项目类别:
-
资助金额:$75.93万
-
财政年份:2021
-
负责人:SAMIA MORA
-
依托单位:
Patient Centered Approaches to Preventing ASCVD Events
-
批准号:10323260
-
项目类别:
-
资助金额:$12.05万
-
财政年份:2018
-
负责人:SAMIA MORA
-
依托单位:
Mentored Patient-Oriented Research for Preventing ASCVD Events
-
批准号:10590992
-
项目类别:
-
资助金额:$12.62万
-
财政年份:2018
-
负责人:SAMIA MORA
-
依托单位:
Total plasma and IgG glycomes, statin therapy and ASCVD events
-
批准号:10464886
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
-
批准号:8918813
-
项目类别:
-
资助金额:$12.57万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
-
批准号:8590899
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
Total plasma and IgG glycomes, statin therapy and ASCVD events
-
批准号:10217226
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
Total plasma and IgG glycomes, statin therapy and ASCVD events
-
批准号:9815089
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
-
批准号:8862528
-
项目类别:
-
资助金额:$43.68万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
-
批准号:9088124
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
-
批准号:8916878
-
项目类别:
-
资助金额:$18.06万
-
财政年份:2013
-
负责人:SAMIA MORA
-
依托单位:
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy
-
批准号:8209065
-
项目类别:
-
资助金额:$13.79万
-
财政年份:2009
-
负责人:SAMIA MORA
-
依托单位:
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy
-
批准号:7758183
-
项目类别:
-
资助金额:$13.72万
-
财政年份:2009
-
负责人:SAMIA MORA
-
依托单位:
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy
-
批准号:8014943
-
项目类别:
-
资助金额:$13.8万
-
财政年份:2009
-
负责人:SAMIA MORA
-
依托单位:
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy
-
批准号:7569548
-
项目类别:
-
资助金额:$13.64万
-
财政年份:2009
-
负责人:SAMIA MORA
-
依托单位:
海外基金